IN VITRO ASSESSMENT OF ANTICANCER ACTIVITY OF SHRIMP DERIVED CHITOSAN AND RELATED APOPTOTIC PROFILE ALTERATION | ||||
| Journal of the Egyptian Society of Parasitology | ||||
| Article 15, Volume 48, Issue 2, August 2018, Page 379-388 PDF (624.04 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.12816/0050445 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| CHRISTINA ATEF FAWZY GHALY1; ASHRAF BAKAAR1; ALY FAHMY MOHAMED2 | ||||
| 1Faculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Egypt. | ||||
| 2VACSERA, Dokki, Giza, Egypt. | ||||
| Abstract | ||||
| Liver breast cancer represents a major health problem worldwide. The present study evaluated the anti-cancer properties of Shrimp derived chitosan on human liver (HepG-2) and breast cancer (MCF7) cell lines. The cytotoxicity of chitosan was determined using MTT assay. Chitosan showed an antiproliferative and cytotoxic effect against (HEPG-2) and (MCF7) cancer cell lines in a dose and cell type dependent manner. The IC50 value of chitosan was 600μg/ml and 348μg/ml for treated HepG-2 and MCF-7 respectively. Anticancer potential of chitosan was monitored via evaluation of cell cycle profile and pro- and anti-apoptotic genes. Cell cycle arrest profile was cell type dependent and occurred insignificantly (P>0.05) during S and G2-M phases in case of HepG2 cells, while it was significantly elevated during G2-M phase in case of MCF-7 treatment. Treated cell lines showed a significant apoptotic % during the Pre-G1 phase (P<0.05). ER and HER-2 as specific markers for MCF-7 and BCL-2 in treated HEPG-2 cells were significantly down regulated (P<0.05), while, p53 was significantly up regulated (P<0.05). | ||||
| Keywords | ||||
| Shrimp derived chitosan; Anti-cancer activity; Apoptotic profile | ||||
|
Statistics Article View: 168 PDF Download: 147 |
||||
